Results 181 to 190 of about 2,169 (197)

AEs of nusinersen, risdiplam and onasemnogene abeparvovec

Reactions Weekly, 2023
openaire   +1 more source

Nusinersen/Risdiplam

Reactions Weekly
openaire   +1 more source

Orphan designation: Risdiplam, Treatment of spinal muscular atrophy

Case Medical Research, 2019
openaire   +2 more sources

Risdiplam (spinale Muskelatrophie, < 2 Monate); Nutzenbewertung gemäß § 35a SGB V

2023
openaire   +1 more source

Risdiplam auch als Tablette verfügbar

DNP – Die Neurologie & Psychiatrie
openaire   +1 more source

In brief: Risdiplam (Evrysdi) for spinal muscular atrophy.

The Medical letter on drugs and therapeutics, 2021
openaire   +1 more source

Switching from Nusinersen to Risdiplam: A Croatian Real-World Experience on Effectiveness and Safety

Journal of Personalized Medicine
Andrej Belančić, Dinko Vitezic, Marta Kučan   +2 more
exaly  

Risdiplam. SMN2 splicing modulator, Treatment of spinal muscular atrophy

Drugs of the Future, 2019
openaire   +1 more source

An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies

European Journal of Paediatric Neurology
Judit Erdos, Doris Giess
exaly  

Risdiplam jako innowacja w leczeniu rdzeniowego zaniku mięśni

2023
Złotnicka, Zuzanna, Kościjański, Sebastian, Zięba, Karolina, Zientek, Justyna, Kwas, Iga, Kuzan, Kacper   +5 more
openaire